X-Health.show - meet the future of healthcare
The X-Health.show brings to you brilliant minds behind programming living cells, tech that detects pre-term delivery in seconds, brain-computer interface or apps that employ AI to match you, your disease with the best treatment.
For the eXtra Health of the future.
You’ll meet visionaries from Switzerland who push the boundaries of healthcare.
Engineers who teamed up with doctors, scientists turned CEOs, doctors programming AI-powered apps, researchers who abandoned university labs to improve your health.
You’ll hear stories of promising startups founders and successful serial entrepreneurs.
Patients who imagine a better way.
You’ll
learn about new disease treatments
understand how AI-driven health tech can improve your life
grasp the way founders innovate
or even, get inspired to jumpstart innovation at your company.
Luckily, the X-Health.show is based in Switzerland, the most innovative country in the world according to World Intellectual Property Organization. For the 12th consecutive year. No wonder when the abundance of funds for innovation meets the ability to commercialize the discoveries.
With notable research institutions situated nearby top pharmaceutical companies, there’s more to expect. More medical innovations, break-through femtech, life changing biotech, developments in digital health, genetic engineering, and wearables, such as smart ring, blood pressure measurement on your wrist or ECG in your pyjama.
Follow the show to meet these amazing innovators.
X-Health.show - meet the future of healthcare
Single-Cell Technologies to Accelerate Drug Development and Cancer Treatment: Dr. Diana Stoycheva, Scailyte
They are great soldiers.
They go after every rouge cell they can find. And kill it.
And they never forget the enemies, always ready to fight back.
We're speaking cancer treatment of the future, in clinical trials today – but not only. Single-cell analysis can serve personalized medicine, in various diseases.
You’ll hear about
- cell therapy to fight cancer
- CAR T cell therapy
- precision medicine and training cells in killing rougue cells
- multiomics analysis
- drug discovery powered and accelerated by AI
- and coming soon: early biomarkers for endometriosis.
Dr. Diana Stoycheva is a Principal Expert Scientist at Scailyte. She specializes in immunology, infectious diseases, and immuno-oncology.
Scailyte, the company she joined, developed an Artificial Intelligence driven platform that supports discovery of complex disease patterns from single-cell data. They’re at the forefront of advancing precision medicine through AI and multiomics analysis.
Find them at https://scailyte.com.
Timestamps:
0:00 Dr Diana Stoycheva and Scailyte
1:20 Single-cell technologies
4:35 What are multiomics
6:17 ScaiVision platform
9:06 Predicting a patient's response to therapy
11:21 Teaching AI
15:46 For drug developers and those who generate complex data
16:04 Founding Scailyte startup
20:44 Dr. Stoycheva's background in immunology and immuno-oncology
23:10 Potential of immunotherapy in treating cancer
23:30 Cell therapy
24:43 CAR T cells
29:50 CAR T cell therapy efficacy
32:20 Singe-cell technologies adoption
37:07 Scailyte-Turnstone Biologics partnership
38:30 How to learn max from early stage trial
39:35 Predictive biomarkers and CDx
42:05 Market access
43:14 Biomarkers for precision medicine
45:19 Cost of personalized cancer treatment
47:24 Future of single-cell data analysis
48:18 Early biomarkers for endometriosis
50:55 Links to Scailyte, Follow X-Health.show, Disclaimer
If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.
The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.
